Our Mission

Designing and delivering srRNA immunotherapies to revolutionize the practice of medicine and improve and save lives

We are applying advanced srRNA technology towards solving a life-threatening problem—drug resistance in cancers—using our proprietary synthetic immune lethality approach.

We are also developing srRNA injections for sustained therapeutic protein expression, to treat inflammatory disorders and other conditions.

We believe that srRNA will bring about the next big breakthroughs in RNA therapeutics and we are excited about its promise for patients.

Our Story (So Far)

Replicate Bioscience was founded to build a best-in-class self-replicating RNA (srRNA) platform from the ground up, to realize the full potential of srRNA in new medicines and vaccines.

Replicate co-founders Nathaniel Wang and Andy Geall previously collaborated on srRNA technologies at Synthetic Genomics and at Novartis Vaccines and Diagnostics, where Wang and Geall led projects to develop RNA vaccines for pandemic response (several years before COVID-19) and cancer immunotherapy.

Wang and Geall started Replicate to answer the question: “If we wanted to create the best self-replicating RNA platform from scratch, how would we do it?” They joined with former colleagues Herbert Kim Lyerly, and Zachary Hartman, professors of cancer research and immunology at Duke University, to explore srRNA as a novel means of preventing or removing drug-resistant cancer mutations—a tactic they dubbed “synthetic immune lethality.” Replicate exclusively licensed and spun this technology out of Duke, building multiple pipeline candidates using this approach.

With the founders’ significant experience in srRNA engineering and manufacturing, Replicate has made rapid progress in identifying many promising srRNA preclinical candidates in oncology and autoimmune diseases. In 2021, Replicate Bioscience received $40 million in Series A funding from leading life sciences venture capital firm ATP (Apple Tree Partners) to advance multiple srRNA programs into clinical development.

Founders

Michael Ehlers, M.D., Ph.D.

Nathaniel Wang, Ph.D.

Andrew Geall, Ph.D.

Herbert Kim Lyerly, M.D.

Zachary Hartman, Ph.D.

Leadership Team

Nathaniel Wang, Ph.D.

Andrew Geall, Ph.D.

Parinaz Aliahmad, Ph.D.

Board of Directors

Michael Ehlers, M.D., Ph.D. (Chair)

Nathaniel Wang, Ph.D.

Seth L. Harrison, M.D.

Joseph A. Yanchik III

Scientific Advisors

Herbert Kim Lyerly, M.D.

Zachary Hartman, Ph.D.

Philip Santangelo, Ph.D.

Jeffrey Ulmer, Ph.D.

Michael Ehlers, M.D., Ph.D.

Dr. Michael Ehlers is chief scientific officer and a venture partner at ATP (Apple Tree Partners), applying expertise gained through a successful career leading research and development at major biopharmaceutical companies. Before joining ATP, Dr. Ehlers was executive vice president for Research and Development at Biogen, where he led discovery sciences, translational medicine, clinical development, and regulatory sciences, with a focus on neurological, immunological, and rare diseases. He significantly expanded and diversified Biogen’s clinical portfolio, transformed its R&D productivity, advanced more than 20 novel clinical candidates, and oversaw global filings and approvals of Spinraza (nusinersen), the first drug approved for spinal muscular atrophy.

Prior to Biogen, Dr. Ehlers was Biotherapeutics group senior vice president and Neuroscience chief scientific officer at Pfizer, where he created and advanced the neuroscience and rare disease portfolios; directed global development activities in biologics design, synthesis, and manufacturing; steered academic collaborations focused on immunology and oncology; and successfully brought 22 compounds into the clinic.

Before entering industry in 2010, Dr. Ehlers was a professor and investigator at the Howard Hughes Medical Institute at Duke University Medical Center, where he pioneered studies on neuronal organelles and the trafficking of neurotransmitter receptors. He has received numerous awards, authored more than 100 scientific papers, and served on multiple editorial boards as well as advisory boards for the National Institutes of Health, private foundations and many other organizations spanning industry, academia and government.

Dr. Ehlers earned a B.S. in chemistry from the California Institute of Technology and holds M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine.

Michael Ehlers, M.D., Ph.D.

Dr. Michael Ehlers is chief scientific officer and a venture partner at ATP (Apple Tree Partners), applying expertise gained through a successful career leading research and development at major biopharmaceutical companies. Before joining ATP, Dr. Ehlers was executive vice president for Research and Development at Biogen, where he led discovery sciences, translational medicine, clinical development, and regulatory sciences, with a focus on neurological, immunological, and rare diseases. He significantly expanded and diversified Biogen’s clinical portfolio, transformed its R&D productivity, advanced more than 20 novel clinical candidates, and oversaw global filings and approvals of Spinraza (nusinersen), the first drug approved for spinal muscular atrophy.

Prior to Biogen, Dr. Ehlers was Biotherapeutics group senior vice president and Neuroscience chief scientific officer at Pfizer, where he created and advanced the neuroscience and rare disease portfolios; directed global development activities in biologics design, synthesis, and manufacturing; steered academic collaborations focused on immunology and oncology; and successfully brought 22 compounds into the clinic.

Before entering industry in 2010, Dr. Ehlers was a professor and investigator at the Howard Hughes Medical Institute at Duke University Medical Center, where he pioneered studies on neuronal organelles and the trafficking of neurotransmitter receptors. He has received numerous awards, authored more than 100 scientific papers, and served on multiple editorial boards as well as advisory boards for the National Institutes of Health, private foundations and many other organizations spanning industry, academia and government.

Dr. Ehlers earned a B.S. in chemistry from the California Institute of Technology and holds M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine.

Nathaniel Wang, Ph.D.

Dr. Nathaniel Wang is the Chief Executive Officer at Replicate Bioscience and cofounder of the company. He has over 15 years of leadership experience in immunology and drug development. He is a pioneer in synthetic, self-replicating RNA technologies and their delivery, including the development of the Replicate srRNA platform. He is also a recognized expert in the fields of immuno-oncology and infectious disease.

Prior to Replicate Bioscience, Dr. Wang was head of the RNA Medicines business unit at Synthetic Genomics, where he developed a self-replicating RNA platform asset. This asset and business unit was sold to Janssen in 2019. At Janssen, he setup a drug discovery and CMC framework and led teams developing compounds in multiple therapeutic spaces using the acquired technologies.

Dr. Wang has played critical roles in both biotech and pharma settings on cross functional teams involving R&D, clinical, business, commercial, legal, and regulatory with strategic oversight of preclinical and clinical assets through commercialization.

Dr. Wang is an inventor on multiple patents for applications of synthetic biology and use of novel technologies for vaccines and therapeutics. He received a Ph.D. in Immunology from The Scripps Research Institute. Prior to this, he earned a B.A. in Molecular Immunology from University of California, at Berkeley.

Nathaniel Wang, Ph.D.

Dr. Nathaniel Wang is the Chief Executive Officer at Replicate Bioscience and cofounder of the company. He has over 15 years of leadership experience in immunology and drug development. He is a pioneer in synthetic, self-replicating RNA technologies and their delivery, including the development of the Replicate srRNA platform. He is also a recognized expert in the fields of immuno-oncology and infectious disease.

Prior to Replicate Bioscience, Dr. Wang was head of the RNA Medicines business unit at Synthetic Genomics, where he developed a self-replicating RNA platform asset. This asset and business unit was sold to Janssen in 2019. At Janssen, he setup a drug discovery and CMC framework and led teams developing compounds in multiple therapeutic spaces using the acquired technologies.

Dr. Wang has played critical roles in both biotech and pharma settings on cross functional teams involving R&D, clinical, business, commercial, legal, and regulatory with strategic oversight of preclinical and clinical assets through commercialization.

Dr. Wang is an inventor on multiple patents for applications of synthetic biology and use of novel technologies for vaccines and therapeutics. He received a Ph.D. in Immunology from The Scripps Research Institute. Prior to this, he earned a B.A. in Molecular Immunology from University of California, at Berkeley.

Herbert Kim Lyerly, M.D.

Dr. Lyerly is the George Barth Geller Professor of Cancer Research, Professor of Surgery, Associate Professor of Pathology and Assistant Professor of Immunology at Duke University in North Carolina. He was appointed in 2008 by President George Bush to serve on the National Cancer Advisory Board, which oversees the National Cancer Institute. He served on the Global Health Sub-Committee of the National Cancer Advisory Board, the National Institute of Health Council of Councils, and the Board of the National Institute of Health Office of AIDS Research. He has been a member of the Scientific Advisory Board of the Susan G. Komen for the Cure Foundation and the Burroughs Wellcome Foundation.

Dr. Lyerly is a highly sought-after consultant and advisor and has served on the Cancer Centers external advisory boards for MD Anderson, University of Michigan, University of Chicago, University of Alabama, University of Arizona, Boston University, and Purdue. He has served as an advisor to the University of Washington, and Case Western Reserve Clinical and Translational Science Institutes.

Dr. Lyerly attended medical school at UCLA, and was trained in surgery at Duke under Dr. David C. Sabiston. He completed postdoctoral training in molecular virology with Dr. Dani Bolognesi and Bryan Cullen at Duke, and joined the Duke Faculty in 1990. As a surgical oncologist, Dr. Lyerly served as the PI of the Duke Breast SPORE, and as the Director of the Duke Comprehensive Cancer Center from 2003 to 2011.

Dr. Lyerly is internationally recognized expert in cancer therapy and immunotherapy and has published over 300 scientific articles and book chapters, and has edited 10 textbooks on surgery, cancer immunotherapy, and novel cancer therapies. He serves on the editorial board of 12 scientific journals. He currently serves on the Board of Directors of Oncosec.

Herbert Kim Lyerly, M.D.

Dr. Lyerly is the George Barth Geller Professor of Cancer Research, Professor of Surgery, Associate Professor of Pathology and Assistant Professor of Immunology at Duke University in North Carolina. He was appointed in 2008 by President George Bush to serve on the National Cancer Advisory Board, which oversees the National Cancer Institute. He served on the Global Health Sub-Committee of the National Cancer Advisory Board, the National Institute of Health Council of Councils, and the Board of the National Institute of Health Office of AIDS Research. He has been a member of the Scientific Advisory Board of the Susan G. Komen for the Cure Foundation and the Burroughs Wellcome Foundation.

Dr. Lyerly is a highly sought-after consultant and advisor and has served on the Cancer Centers external advisory boards for MD Anderson, University of Michigan, University of Chicago, University of Alabama, University of Arizona, Boston University, and Purdue. He has served as an advisor to the University of Washington, and Case Western Reserve Clinical and Translational Science Institutes.

Dr. Lyerly attended medical school at UCLA, and was trained in surgery at Duke under Dr. David C. Sabiston. He completed postdoctoral training in molecular virology with Dr. Dani Bolognesi and Bryan Cullen at Duke, and joined the Duke Faculty in 1990. As a surgical oncologist, Dr. Lyerly served as the PI of the Duke Breast SPORE, and as the Director of the Duke Comprehensive Cancer Center from 2003 to 2011.

Dr. Lyerly is internationally recognized expert in cancer therapy and immunotherapy and has published over 300 scientific articles and book chapters, and has edited 10 textbooks on surgery, cancer immunotherapy, and novel cancer therapies. He serves on the editorial board of 12 scientific journals. He currently serves on the Board of Directors of Oncosec.

Andrew Geall, Ph.D.

Dr. Andrew Geall is the Chief Development Officer at Replicate Bioscience and cofounder of the company. Dr. Geall has over 20 years of professional experience in the development of drug delivery systems and is a pioneer in the fields of mRNA vaccines and nucleic acid delivery. He is an inventor on 41 patent families, with 505 applications and 203 issued patents in multiple jurisdictions.

Prior to joining Replicate, Dr. Geall was Chief Scientific Officer at Precision NanoSystems Inc. (PNI). Here, he was focused on the creation of transformative nanoparticle medicines using their proprietary LNP delivery systems and microfluidic formulation platform. He has also held positions as Vice President of Formulations, Analytics and Chemistry at Avidity Biosciences, where he pioneered the development of their antibody-oligonucleotide conjugate delivery platform. As a member of the Executive Management, he helped raise over $100 million in venture capital and take the company public in June 2020 with an initial public stock offering of $259 million.

Prior to Avidity, he led mRNA vaccines in the Vaccine division of Novartis. Over 7 years, he created a global team and was Principal Investigator on a Defense Advanced Research Project Agency (DARPA) contract to develop self-amplifying mRNA vaccines. Dr. Geall also had a two-year tenure at Novartis Pharmaceuticals AG, where he was the Global siRNA Formulation Team Leader, responsible for the design and implementation of the siRNA delivery strategy.

Dr. Geall received his pharmacy degree from the University of Bath in the UK and went on to do his pre-registration training, as a hospital Pharmacist, in the aseptic dispensing unit at St Helens and Knowsley Trust Hospitals. He then obtained his PhD at University of Bath in non-viral gene delivery.

Zachary Hartman, Ph.D.

Dr. Zachary C. Hartman is an assistant professor at Duke University in the Departments of Surgery and Pathology and the Associate Director for Discovery Research in the Center for Applied Therapeutics. Dr. Hartman received his PhD in Genetics and Genomics from Duke University in 2006 and did post-doctoral fellowships focusing on tumor immunology and breast cancer at both Duke and the MD Anderson Cancer Center. In 2012, he became a faculty member at Duke and developed a research program focused on the study of immunity and inflammation in the breast cancer, as well as strategies to modulate and direct immunity against breast cancer. This spans the use of novel immunotherapeutic agents and development of vaccines to specific oncogenic targets, which are now in ongoing clinical trials at Duke. This work has been supported through research grants from the National Institute of Health and Department of Defense, as well as organizations such as the American Cancer Society and Susan G. Komen for the Cure. For his immuno-oncology research, Dr. Hartman has been the recipient of multiple awards, including the Paul Calabresi Award for Clinical Oncology and AACR Scholar awards and has been specifically recognized and supported by Susan G Komen as a recipient of the Jon Shevell Young Scientist and Career Catalyst Awards.

Zachary Hartman, Ph.D.

Dr. Zachary C. Hartman is an assistant professor at Duke University in the Departments of Surgery and Pathology and the Associate Director for Discovery Research in the Center for Applied Therapeutics. Dr. Hartman received his PhD in Genetics and Genomics from Duke University in 2006 and did post-doctoral fellowships focusing on tumor immunology and breast cancer at both Duke and the MD Anderson Cancer Center. In 2012, he became a faculty member at Duke and developed a research program focused on the study of immunity and inflammation in the breast cancer, as well as strategies to modulate and direct immunity against breast cancer. This spans the use of novel immunotherapeutic agents and development of vaccines to specific oncogenic targets, which are now in ongoing clinical trials at Duke. This work has been supported through research grants from the National Institute of Health and Department of Defense, as well as organizations such as the American Cancer Society and Susan G. Komen for the Cure. For his immuno-oncology research, Dr. Hartman has been the recipient of multiple awards, including the Paul Calabresi Award for Clinical Oncology and AACR Scholar awards and has been specifically recognized and supported by Susan G Komen as a recipient of the Jon Shevell Young Scientist and Career Catalyst Awards.

Parinaz (Paris) Aliahmad, Ph.D.

Dr. Parinaz (Paris) Aliahmad is Head of Research at Replicate Bioscience. She has expertise in drug development, including both small molecules therapeutics and vaccines (inclusive of nucleic acid, protein, and viral vector-based platforms) and comprehensive knowledge of the immune system as it relates to establishing host immunity with vaccines and immunotherapies, as well dampening inflammation in autoimmune disease.

Prior to Replicate Bioscience, Dr. Aliahmad was at Arena Pharmaceuticals heading development of their early-stage pipeline. She has also held positions at both Janssen and Synthetic Genomics, leading translational studies of a self-replicating RNA platform asset for infectious disease and oncology vaccines.

Dr. Aliahmad is an inventor on multiple patents for applications of synthetic biology and use of novel technologies for vaccines and therapeutics. She received a Ph.D. in Immunology from The Scripps Research Institute. Prior to this, she earned a M.S. in Immunology from the University of Toronto and a B.S. in Microbiology & Immunology from McGill University.

Philip Santangelo, Ph.D.

Dr. Philip J. Santangelo is a Professor in the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech. He graduated from Polytechnic University (currently NYU Tandon School of Engineering) in 1991 with a B.S. in Aerospace Engineering. In 1998, he obtained his Ph.D. in Engineering from the University of California at Davis and followed his Ph.D. with a postdoctoral fellowship at Sandia National Laboratories in Livermore, California. Dr. Santangelo returned to academia as a postdoctoral fellow and then as a research faculty member at Georgia Tech under Dr. Gang Bao until his current appointment at Georgia Tech. Dr. Santangelo’s current research focuses on the development of imaging technology for the study of RNA regulation and the pathogenesis of RNA viruses, and the development of synthetic mRNA-based therapeutics and vaccines. To date, the results of his work have been published in high impact journals such as Nature Methods, Nature Nanotechnology, Nature Communications, Nature BME, Science, and Nucleic Acids Research.

Jeffrey Ulmer, Ph.D.

During his 30-year career in vaccines R&D at Merck Research Laboratories, Chiron Corporation, Novartis Vaccines and GSK, Dr. Jeffrey Ulmer’s leadership roles and responsibilities have included: Platform Technology Leader (DNA, RNA vaccines), Project Leader (Tuberculosis, SARS), Department Head (Immunology & Cell Biology), US Site Head for Research, Global Function Head (External Research), Head, Preclinical R&D, and Program Head, Technical R&D. Dr. Ulmer received his Ph.D. in biochemistry from McGill University and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. He has published over 200 scientific articles and is an inventor on 11 patents.

Joseph A. Yanchik III

Joseph Yanchik, a venture partner at ATP (Apple Tree Partners), has been founding and funding life science companies for more than 20 years. In 2005, he founded ATP portfolio company Tokai Pharmaceuticals, focused on biopharmaceutical treatments for prostate cancer, serving as president and CEO from 2005 to 2008 and then as a director through 2017. Concurrently, he founded ATP portfolio company Aileron Therapeutics, focused on developing a novel class of stabilized cell-permeating peptides called stapled peptides, for cancer and other diseases. He established a $1.1 billion partnership between Aileron Therapeutics and Roche Pharmaceuticals and led Aileron from inception to public listing, serving as president, CEO, and director from 2006 to 2018. Previously, Mr. Yanchik served as vice president of corporate development at Mendel Biotechnology, an agricultural biotech company, and founded and served as chief financial officer of Poetic Genetics, a gene therapy company. He began his career practicing corporate and securities law at Cahill Gordon & Reindel, where he specialized in public securities offerings, high-yield debt financings, and M&A. He then moved to Venture Law Group in Menlo Park, where he specialized in financing early-stage life science and technology companies.

Mr. Yanchik received a B.B.A. from Loyola College in Maryland and a J.D. from the Villanova University School of Law, where he was managing editor of the Law Review. He is a member of the New York, California, and District of Columbia bars.

Seth L. Harrison, M.D.

Dr. Seth Harrison is founder and managing partner of ATP (Apple Tree Partners), a leading life sciences venture capital firm with $2.65 in committed capital. To date, ATP has launched or invested in over 30 transformative companies focused on delivering cutting-edge therapies for unmet medical needs, out of which 19 so far have gone public or been acquired. Prior to starting ATP in 1999, Dr. Harrison was a general partner at Oak Investment Partners, and before that a venture partner at Sevin Rosen Funds. From 2002 to 2010, he also served on the board of the International Partnership for Microbicides.

Dr. Harrison received an A.B. from Princeton University, an M.D. and MBA both from Columbia University, and completed a surgery internship at the Presbyterian Hospital in the City of New York.